V
VIRX

Veritable’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Veritable’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,836
Closed -$36.3K – 920
2022
Q4 		$36.3K Hold
24,836
– – ﹤0.01% 858
2022
Q3 		$106K Hold
24,836
– – ﹤0.01% 771
2022
Q2 		$96K Hold
24,836
– – ﹤0.01% 860
2022
Q1 		$118K Buy
+24,836
New +$74.8K ﹤0.01% 885

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Veritable's VIRX Position: Q1 2023 in Review

Veritable sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2023, closing a stake of 24,836 shares — an estimated $36.3K sold.

Veritable first reported a position in VIRX in Q1 2022 and held it in 4 quarters. The position peaked at $118K in Q1 2022. 48 funds tracked by Wall St. Rank hold VIRX as of Q1 2023.

  • Veritable reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Veritable sold 24,836 Viracta Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $36.3K.
  • Veritable first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Veritable's Viracta Therapeutics, Inc. Common Stock position peaked at $118K in Q1 2022.
  • 48 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Veritable's 13F filing for Q1 2023, filed 12 May 2023.